RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Favorable Benefit-to-Risk Profile of Everolimus Upheld in Updated Safety Analyses
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 5
SP 16
OP 17
DO 10.1177/155989771105012
UL http://mdc.sagepub.com/content/11/5/16.abstract
AB The updated safety results of the RADIANT-2 and −3 Trials have demonstrated a favorable benefit-to-risk profile of everolimus for progressive advanced neuroendocrine tumors. The findings are consistent with those of the initial safety analyses and the known safety profile of the drug in patients with cancer.